

### **CONTINGENT EXTENSION REQUEST**

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

### **SUMMARY OF AMENDMENTS**

1. ☐ If checked, an abstract (an amended abstract) is submitted herewith.
2. ☒ If checked, amendment(s) to the drawings are submitted herewith.
3. ☒ If checked, amendment(s) to the specification are submitted herewith.
4. ☒ If checked, amendment(s) to the claims are submitted herewith.

### **AMENDMENT(S) TO THE SPECIFICATION**

Please insert at page 1, after the title, the following paragraph:

### **--CROSS REFERENCE TO RELATED APPLICATIONS**

This is a divisional of U.S. Patent Application Serial No. 09/330,799, filed June 11, 1999, now allowed, which is a Continuation-in-part of U.S. Patent Application Serial No. 09/096,284, filed June 11, 1998, now U.S. Patent No. 6,465,445, which issued October 12, 2002 in the name of Fernand Labrie and entitled "MEDICAL USES OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH SEX STEROID PRECURSORS".--